Table 1.
Cell focus | Method | Method adapted from | IHC confirmation | PCR Confirmation | References | Year | ||||
---|---|---|---|---|---|---|---|---|---|---|
Stage | Culture | Days | Marker | Day | Marker | Day | ||||
General | SFEBq | Nakano et al. | PAX6 | 24 | 50 | 2015 | ||||
Embryoid bodies | Floating | 0–18 | CHX10 | 24 | ||||||
Neurospheres | Floating | 18+ | MITF | 24 (low) | ||||||
PKCa | 24 | |||||||||
BRN3 | 50 | |||||||||
Crx | 50 | |||||||||
NRL | 150 | |||||||||
General | Embryoid bodies | Floating | 0-6 | Keller et al. | PAX6 | 10 | PAX6 | 6 | 54 | 2009 |
Rosettes | Adherent | 6–16 | RAX | 10 | RAX | 6 | ||||
Neurospheres | Floating | 16+ | CHX10 | 30 | MITF | 16 | ||||
MITF | 30 | CHX10 | 23 | |||||||
ZO-1 | 30 | RPE65 | 40 | |||||||
CRX | 60 | |||||||||
OPSIN | 70 | |||||||||
General | Embryoid bodies | Floating | 0-6 | Meyer et al. | PAX6 | 20 | PAX6 | 20 | 57 | 2011 |
Rosettes | Adherent | 6-16 | CHX10 | 20–25 | BIII | 20 | ||||
Neurospheres | Floating | 16+ | ISL1 | 20–25 | BRN3 | 30 | ||||
Seperation of Retinal spheres | Floating | 20-25 | ZO-1 | 40 | CRX | 30 | ||||
MITF | 40 | MITF | 40 | |||||||
BRN3 | 80 | RPE65 | 40 | |||||||
PKCa | 80 | BEST1 | 40 | |||||||
CRX | 80 | NRL | 60 | |||||||
RCVRN | 80 | |||||||||
NRL | 80 | |||||||||
General | SFEBq | PAX6 | 20 | PAX6 | 10 | 46 | 2009 | |||
Embryoid Bodies | Floating | 0-21 | RAX | 20 | MITF | 10 | ||||
Neurospheres | Floating | 21+ | CHX10 | 20 | RAX | 20 | ||||
PRs | Adherent | 90 | MITF | 35 | CHX10 | 20 | ||||
ZO-1 | 100 | RPE65 | 120 | |||||||
RHO | 140 | |||||||||
General | Embryoid Bodies | Adherent | 0-28 | PAX6 | 14 | LHX2 | 14 | 48 | 2017 | |
Neurospheres | Floating | 28+ | RAX | 14 | MITF | 14 | ||||
LHX2 | 14 | RAX | 14 | |||||||
MITF | 14 | PAX6 | 14 | |||||||
CHX10 | 14 | VSX2 | 14 | |||||||
BRN3 | 21 | CRX | 14 | |||||||
CRX | 21 | BRN3 | 21 | |||||||
RCVRN | 42 | RCVRN | 35 | |||||||
General | SFEBq | Nakano et al. | RAX | 7 | VSX2 | 10 | 58 | 2016 | ||
Embryoid Bodies | Floating | 0-18 | PAX6 | 7 | RAX | 10 | ||||
Neurospheres | Floating | 18-41 | LHX2 | 7 | ISL1 | 10 | ||||
MITF | 10 | ATOH7 | 10 | |||||||
VSX2 | 10 | BRN3 | 10 | |||||||
BRN3 | 41 | RCVRN | 10 | |||||||
CRX | 15 | |||||||||
PAX6 | 15 | |||||||||
NRL | 18 | |||||||||
General | Embryoid Bodies | Matrigel | 0-4 | Ohlemacher et al. and Zhu et al. | RAX | 4 | This study | 2019 | ||
Rosettes | Adherent | 4-11 | PAX6 | 4 | ||||||
Neurospheres | Floating | 11+ | SOX2 | 4 | ||||||
ISL1 | 28 | |||||||||
HuC/D | 28 | |||||||||
PKCa | 28 | |||||||||
ZO-1 | 56 | |||||||||
RCVRN | 91 | |||||||||
GFAP | 96 | |||||||||
RBPMS | 96 | |||||||||
RHO | 168 | |||||||||
General | Embryoid Bodies | Floating | 0-7 | Meyer et al. | PAX6 | 8 | PAX6 | 4 | 27 | 2014 |
Rosettes | Adherent | 7-28 | RAX | 12 | LHX2 | 4 | ||||
Neurospheres | Floating | 28+ | MITF | 14 | RAX | 8 | ||||
VSX2 | 14 | |||||||||
HuC/D | 35 | |||||||||
BRN3 | 35 | |||||||||
RCVRN | 63 | |||||||||
RHO | 119 | |||||||||
General/PR | SFEBq | PAX6 | 18 | 18 | 2012 | |||||
Embryoid Bodies | Floating | 0-18 | CHX10 | 18 | ||||||
Neurospheres | Floating | 18-126 | MITF | 18 | ||||||
PKCa | 18 | |||||||||
BRN3 | 30 | |||||||||
RCVRN | 43 | |||||||||
NRL | 126 | |||||||||
RHO | 126 | |||||||||
RGC | Embryoid Bodies | Floating | 0-4 | HuC/D | 25 | RAX | 3 | 60 | 2016 | |
RGCs | Adherent | 4-30 | BIII | 25 | ISL1 | 3 | ||||
BRN3a | 45 | ATOH7 | 3 | |||||||
PAX6 | 3 | |||||||||
BRN3B | 3 | |||||||||
MITF | 8 | |||||||||
RPE65 | 11 | |||||||||
RGC | Embryoid Bodies | Floating | 0-4 | MATH5 | 20 | RAX | 4 | 28 | 2018 | |
Rosettes | Adherent | 4-8 | BRN3B | 40 | LHX2 | 4 | ||||
RGCs | Adherent | 8-40 | ISL1 | 40 | CHX10 | 12 | ||||
MATH5 | 12 | |||||||||
CRX | 12 (low) | |||||||||
MITF | 12 | |||||||||
BRN3B | 19 | |||||||||
RGC | Rosettes | Adherent | 0-14 | RAX | 14 | 51 | 2014 | |||
Neurospheres | Floating | 14-40 | PAX6 | 14 | ||||||
ZO-1 | 14 | |||||||||
BRN3 | 40 | |||||||||
RGC | SFEBq | Nakano et al. | RAX | 24 | RAX | 6 | 49 | 2015 | ||
Neurospheres | Floating | 0-26/29 | PAX6 | 24 | PAX6 | 6 | ||||
RGCs | Adherent | 26/29+ | MATH5 | 34 | CRX | 6 | ||||
BRN3 | 34 | CHX10 | 6 | |||||||
CRX | 34 | PKCa | 18 | |||||||
MITF | 18 | |||||||||
BRN3 | 24 | |||||||||
MATH5 | 24 | |||||||||
RGC/RPE | Embryoid bodies | Floating | 0–7 | Meyer et al. | PAX6 | 20 | PAX6 | 20 | 19 | 2015 |
Rosettes | Adherent | 7-16 | CHX10 | 30 | RAX | 20 | ||||
Neurospheres | Floating | 16+ | BRN3 | 40 | CHX10 | 30 | ||||
Seperation of Retinal spheres | Floating | 20-25 | RCVRN | 50 | BRN3 | 40 | ||||
HuC/D | 70 | ISL1 | 50 | |||||||
ISL1 | 70 | HuC/D | 50 | |||||||
Floating | RBPMS | 70 | ||||||||
RPE | Embryoid bodies | Floating | 0–7 | Pax6 | 13 | 53 | 2014 | |||
Rosettes | Adherent | 7–16 | MITF | 13 | ||||||
Neurospheres | Floating | 16+ | VSX2 | 15 | ||||||
ZO-1 | 60 | |||||||||
RPE | Embryoid Bodies | Matrigel | 0-5 | PAX6 | 3 | PAX6 | 5 | 20 | 2013 | |
RPE | Adherent | 5-25 | ZO-1 | 1 (EB) | RAX | 5 | ||||
RAX | 5 | CHX10 | 5 | |||||||
CHX10 | 15 | MITF | 10 | |||||||
PR/RPE | Embryoid Bodies | Floating | 0-30 | Rho | 45 | PAX6 | 15 | 47 | 2012 | |
Neurospheres | Adherent | 30-60 | OPN1SW | 45 | RPE65 | 30 | ||||
RPE65 | 45 | CHX10 | 45 | |||||||
ZO-1 | 45 | CRX | 60 | |||||||
RCVRN | 60 | |||||||||
PR | SFEBq | Nakano et al. | PAX6 | 37 | 56 | 2015 | ||||
Embryoid Bodies | Floating | 0-12 | BRN3b | 37 | ||||||
Neurospheres | Floating | 12-90 | CRX | 37 | ||||||
RCVRN | 37 | |||||||||
PKCa | 67 | |||||||||
Arr | 67 | |||||||||
NRL | 67 | |||||||||
OPN1SW | 90 | |||||||||
PR | Embryoid Bodies | Floating | 0-6 | Meyer et al. | PAX6 | 56 | RAX | 56 | 55 | 2018 |
Neurospheres | Adherent | 6+ | RAX | 56 | VSX2 | 56 | ||||
RCVRN | 56 | PAX6 | 56 | |||||||
CRX | 56 | RCVRN | 56 | |||||||
BRN3B | 140 | CRX | 56 | |||||||
MITF | 56 | |||||||||
PR | SFEBq | Nakano et al. | BRN3 | 35 | OPN1SW | 12 | 36 | 2017 | ||
Embryoid Bodies | Floating | 0-10/12 | RCVRN | 45 | VSX2 | 30 | ||||
Neurospheres | Floating | 10/12+ | RHO | 160 | RCVRN | 30 | ||||
CRX | 65 | |||||||||
NRL | 100 | |||||||||
ARR3 | 100 |